Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIa, Multicenter, Randomized, Controlled, Open Label Study to Evaluate the Efficacy of SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects With a Neoplastic Disease

Trial Profile

A Phase IIa, Multicenter, Randomized, Controlled, Open Label Study to Evaluate the Efficacy of SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects With a Neoplastic Disease

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Arazasetron (Primary) ; Cisplatin
  • Indications Chemotherapy-induced damage; Hearing loss
  • Focus Proof of concept; Therapeutic Use
  • Acronyms NOTOXIS
  • Sponsors Sensorion
  • Most Recent Events

    • 14 Mar 2024 According to a Sensorion media release, company will communicate preliminary efficacy and safety data of this POC Phase 2a clinical study of SENS-401 in CIO during the World Congress of Audiology, held on September 19-22, 2024, in Paris, France.
    • 09 Feb 2024 According to a Sensorion media release, the company will present preliminary safety and efficacy data at World Congress of Audiology in H2 2024.
    • 18 Dec 2023 According to a Sensorion media release, recruitment is progressing at a sustained path, with 11 clinical centers open to date. Management team will communicate further updates during the World Congress of Audiology 2024.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top